English

Pharmaceutical companies

The Big Question

The rising threat of antimicrobial resistance and its economic toll

ADVERTISEMENT

ADVERTISEMENT

More about this topic

Health news

Eli Lilly bets on AI-powered drugs in new deal with Insilico Medicine

Eli Lilly has partnered with AI biotech Insilico Medicine for exclusive global rights to develop and commercialise medicines designed entirely by artificial intelligence.

Health news

Antibiotic pipeline shrinks as drug-resistance rises, report finds

The antibiotic pipeline has shrunk 35 percent in five years, falling behind growing antimicrobial resistance worldwide, according to a new report.

Health news

New oral pill outperforms weight-loss alternatives, trial finds

Eli Lilly’s new oral pill, orforglipron, led to up to 8% weight loss in clinical trials, outperforming existing oral semaglutide alternatives.

Health news

Why weight loss drugs aren't Denmark's trump card in Greenland dispute

Novo Nordisk, the Danish manufacturer of weight-loss drugs Ozempic and Wegovy, has a large market share in the US. But it's not enough to put pressure on US President Donald Trump's administration during Greenland talks, experts say.

ADVERTISEMENT

Health news

Could green inhalers cut health care’s climate footprint?

As climate change worsens respiratory diseases, doctors and drugmakers are exploring earlier diagnosis and low-carbon inhalers to cut emissions from care and protect patients.

Health news

New gonorrhoea treatment could help beat drug-resistant infections

A new single-dose treatment for gonorrhoea, expected to be approved in the coming days, could be the key to tackling the infection amid rising antibiotic resistance.

Health news

EU unveils new pharma package to boost industry

The European Union has agreed on new pharmaceutical rules introducing new incentives to boost the pharmaceutical industry amid accessibility concerns.

Business

Pharma market shake-up: Bayer jumps, Novo Nordisk sinks 10%

Shares of Danish pharmaceutical giant Novo Nordisk fell sharply after its Alzheimer's drug failed to slow progression of the disease in a trial. Meanwhile, Germany's Bayer said their stroke-prevention drug showed positive results, pushing the share price through the roof.

Markets

AstraZeneca to list shares in New York, without leaving the UK

Amid concerns it might leave the UK, the pharma giant reaffirmed its commitment to the country, keeping its headquarters, primary listing, and tax base there.

Economy

The Ozempic ripple: When a single jab moves an entire market

As GLP-1 use spreads, grocers and restaurants see lighter baskets, airlines predict fuel savings and health systems eye lower costs—while Denmark sees a clipped GDP.

Health news

Young children are given ADHD drugs too quickly, study finds

US paediatricians often prescribe medication immediately after diagnosing 4- and 5-year-olds with ADHD, according to the analysis.

Health news

EU approves new twice-yearly jab to prevent HIV

The new treatment option comes amid a rise in HIV cases in parts of Europe.

Health news

Eli Lilly’s daily weight loss pill succeeds in latest trial

Lilly said it plans to ask regulators to approve the drug by the end of 2025.

Healthcare

Eli Lilly hikes UK price of blockbuster weight loss drug Mounjaro

The price hike is not expected to affect access for patients who receive Mounjaro through the National Health Service (NHS).

Health news

Experimental pill helped with weight loss in Eli Lilly trial

Study participants lost an average of 12.4 per cent of their body weight over 72 weeks.

Markets

Pfizer earnings strong despite Trump’s new 'up to 250%' tariff threat

Pfizer beat earnings expectations and improved its outlook for the rest of the year, despite fresh statements from Trump announcing pharma tariffs next week.